Role of standardized biomarkers in addressing MRI limitations

Panelists discuss how standardized biomarkers like IsoPSA can address limitations of MRI in prostate cancer detection, particularly in cases with inconclusive imaging results. They note that MRI, while valuable, is not infallible and can miss clinically significant cancers or produce ambiguous findings that complicate clinical decisions.

Panelists discuss how biomarkers provide a complementary safeguard, offering sustained negative predictive value that can inform biopsy deferral or confirm risk assessment. By integrating biomarker results with imaging, clinicians can reduce unnecessary procedures while still capturing patients most likely to benefit from intervention.

Panelists discuss how risk tolerance varies among patients and physicians, making tools like IsoPSA useful in navigating diagnostic uncertainty. They emphasize that biomarkers can play a central role in creating personalized diagnostic pathways, balancing accuracy with patient comfort and safety.